	US 11,753,668 B2
	Copper supplementation for control of glycosylation in mammalian cell culture process
Fernie Mitchelson, Morrisville, NC (US); Erik Hughes, Raleigh, NC (US); Jessica Mondia, Arlington, MA (US); and Robin Parish Hyde-Deruyscher, Chapel Hill, NC (US)
Assigned to Biogen MA Inc., Cambridge, MA (US)
Filed by Biogen MA Inc., Cambridge, MA (US)
Filed on Feb. 2, 2022, as Appl. No. 17/591,171.
Application 17/591,171 is a continuation of application No. 15/519,731, granted, now 11,268,119, previously published as PCT/US2015/055856, filed on Oct. 16, 2015.
Claims priority of provisional application 62/065,454, filed on Oct. 17, 2014.
Prior Publication US 2022/0315973 A1, Oct. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12P 21/00 (2006.01); C12N 5/00 (2006.01); C07K 16/28 (2006.01)

CPC C12P 21/005 (2013.01) [C07K 16/2839 (2013.01); C12N 5/0018 (2013.01); C07K 2317/14 (2013.01); C07K 2317/40 (2013.01); C07K 2317/41 (2013.01); C12N 2500/10 (2013.01); C12N 2500/20 (2013.01); C12N 2511/00 (2013.01); C12N 2513/00 (2013.01)]

16 Claims

1. A method for achieving a predetermined galactosylation profile of an anti-α4-integrin antibody, the method comprising:

culturing host cells producing the anti-a4-integrin antibody in a cell culture comprising an amount of copper within a target copper concentration range, wherein the target copper concentration range in the cell culture is between 20 nM and 50 nM at day 0 of the culturing wherein the target copper concentration range is achieved by supplementing the cell culture with a yeast hydrolysate comprising copper.